Working… Menu

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00056082
Recruitment Status : Completed
First Posted : March 7, 2003
Last Update Posted : February 15, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Carol Fabian, MD, University of Kansas Medical Center

Brief Summary:

RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women.

PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing breast cancer in premenopausal women who are at risk of developing cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: celecoxib Phase 2

Detailed Description:


  • Determine the change in proliferation in benign breast epithelial cells as measured by Ki-67/MIB-1 in premenopausal women at high risk for estrogen receptor-negative breast cancer treated with celecoxib.
  • Determine the feasibility of this regimen by dropout rate of these patients during 12 months of treatment and compliance.
  • Determine the proportion of these women likely to express cyclooxygenase-2 protein (COX-2) in at least 10% of benign ductal epithelial cells.
  • Compare the success rate of obtaining adequate ductal epithelial cells by random periareolar fine needle aspiration (FNA) and ductal lavage in these patients before vs after 12 months of a prevention intervention.
  • Assess pain associated with FNA and ductal lavage in these women.
  • Correlate, if possible, serum proteomics pattern with cytologic assessment and mammographic density at baseline and at 12 months in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral celecoxib twice daily. Treatment continues for 12 months in the absence of clinical evidence of cancer confirmed by biopsy or unacceptable toxicity.

Patients are assessed at baseline and at 12 months for mammographic breast density, serum hormone levels, and serum IGF-1/IGFBP-3. Patients undergo ductal lavage or fine needle aspiration for assessment of supernatant proteomics and breast biomarkers.

Patients are followed at 2 weeks and then annually for 5 years.

PROJECTED ACCRUAL: A total of 110 patients will be accrued for this study within 10-14 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 110 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Study Start Date : January 2003
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Celecoxib

Arm Intervention/treatment
Experimental: Celecoxib 400 mg bid
Celecoxib 400 mg bid
Drug: celecoxib
Celecoxib daily for 12 months
Other Name: Celebrex

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes


  • Increased risk for breast cancer on the basis of at least 1 of the following criteria:

    • Five-year Gail risk at least 1.7% or a calculated risk at least 5 times the average for age group

      • 20-29 years old - calculated 5-year Gail risk is at least 0.1%
      • 30-39 years old - calculated 5-year Gail risk is at least 1.0%
      • 40 and over - calculated 5-year Gail risk is at least 1.7%
    • Known BRCA1/BRCA2 mutation carrier
    • Family history consistent with hereditary breast cancer, as defined by any of the following circumstances:

      • At least 4 relatives with breast cancer at any age
      • At least 2 first-degree relatives diagnosed with breast cancer at age 50 or younger
      • Breast and ovarian cancer diagnosed in the same relative
      • At least 2 occurrences of breast cancer and 1 occurrence of ovarian cancer at any age in the same family
    • Prior biopsy exhibiting atypical hyperplasia, lobular cancer in situ, ductal carcinoma in situ (DCIS)*, or invasive cancer** NOTE: *If DCIS or T1a or T1b disease was found, at least 2 months must have elapsed since prior surgery and/or radiotherapy to the involved breast

NOTE: **Prior invasive cancer (T1c, T2, or T3) must have been diagnosed at least 2 years before study and be estrogen receptor-negative, node negative

  • Must have had a random periareolar fine needle aspiration successfully performed within the past 3 months, with at least 1,000 cells on cytology slide and 3 additional slides for biomarker analysis (1 with at least 500 cells for Ki-67 and 2 with at least 100 ductal cells for estrogen receptors and COX-2)
  • Hormone receptor status:

    • Estrogen receptor negative



  • 18 to 55


  • Female

Menopausal status

  • Premenopausal, defined as menstrual periods estimated to occur every 21 to 35 days over the past 6 months

Performance status

  • Not specified

Life expectancy

  • At least 5 years


  • Absolute granulocyte count at least 1,000/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10 g/dL
  • No bleeding diathesis within the past year


  • Bilirubin no greater than 2.0 mg/dL
  • Albumin at least 3.0 g/dL
  • AST and ALT no greater than 2 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2 times ULN
  • No severe liver disease requiring treatment


  • Creatinine no greater than 1.5 mg/dL


  • No high blood pressure not controlled by medication
  • No history of angina
  • No history of cardiovascular disease
  • No history of deep vein thrombosis


  • No history of pulmonary embolism


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior allergy to sulfa, COX-2 inhibitors, or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • No history of an ulcer requiring treatment
  • No history of ulcerative colitis
  • No inflammatory bowel disease
  • No body mass index > 33
  • No history of diabetes
  • No prior metastatic malignancy of any kind
  • No complications of alcoholism requiring hospitalization
  • No concurrent asthma being treated


Biologic therapy

  • Not specified


  • At least 6 months since prior chemotherapy

Endocrine therapy

  • At least 6 months since prior antihormone therapy (e.g., selective estrogen-receptor modulators or aromatase inhibitors)
  • Anticipated use of oral or IV corticosteroids must be less than 2 weeks per year
  • No change (stop or start) in hormonal therapy within the past 6 months (e.g., estrogen, progesterone, oral contraceptives, or fertility agents)


  • See Disease Characteristics
  • No prior radiotherapy to the contralateral breast involved in the study treatment


  • See Disease Characteristics


  • At least 3 weeks since prior aspirin, rofecoxib, celecoxib, other COX-2 inhibitors, or NSAIDs
  • No concurrent anticoagulants
  • No other concurrent NSAIDs
  • No chronic angiotensin-converting enzyme inhibitors
  • No chronic furosemide*
  • No chronic fluconazole*
  • No chronic lithium NOTE: *Occasional concurrent use allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00056082

Layout table for location information
United States, Illinois
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
United States, Kansas
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, United States, 66160-7820
United States, Oklahoma
Oklahoma University Medical Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Kansas Medical Center
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Carol J. Fabian, MD University of Kansas

Layout table for additonal information
Responsible Party: Carol Fabian, MD, Director, Breast Cancer Prevention Unit, University of Kansas Medical Center Identifier: NCT00056082     History of Changes
Other Study ID Numbers: KUMC-HSC-8919-02
CDR0000271935 ( Registry Identifier: PDQ (Physician Data Query) )
N01-CN-15135 ( Other Grant/Funding Number: NCI )
First Posted: March 7, 2003    Key Record Dates
Last Update Posted: February 15, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Global results will be published
Keywords provided by Carol Fabian, MD, University of Kansas Medical Center:
breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action